GlassScriptPhysician profile
Michael D Hodgeson
NPI 1447284484
$2,028.44
in general payments reported to CMS, 2019-2025
22 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.46 · 2022: $241 · 2023: $570 · 2024: $596 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $224.34 | 2022-2025 | |
| Dexcom, INC. | $218.49 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $170.04 | 2023-2025 | |
| Pfizer INC. | $140.09 | 2022-2025 | |
| Glaxosmithkline, LLC. | $117.26 | 2022-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $111.14 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $98.09 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $95.41 | 2023-2025 | Airsupra, Farxiga |
| Boston Scientific Corporation | $86.79 | 2024-2025 | Wavewriter Alpha Prime 16, Bodyguardian |
| Lilly USA, LLC | $74.95 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $58.71 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.97 | 2023-2024 | Jardiance, Ofev |
| Amgen INC. | $45.83 | 2024-2025 | Repatha, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $23.47 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.19 | 2024 | Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $18.08 | 2022 | |
| Dynavax Technologies Corporation | $17.98 | 2024 | Heplisav-B |
| Xeris Pharmaceuticals, INC. | $17.72 | 2022 | |
| Daiichi Sankyo INC. | $16.52 | 2024 | Injectafer |
| Aytu Biopharma, INC. | $16.46 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hodgeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.